Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children

被引:6
作者
Stolbova, Sarka [1 ,2 ]
Bezdicka, Martin [1 ,2 ]
Prohaszka, Zoltan [3 ,4 ]
Csuka, Dorottya [3 ,4 ]
Hrachovinova, Ingrid [5 ]
Burkert, Jan [2 ,6 ]
Simankova, Nadezda [1 ,2 ]
Pruhova, SStepanka [1 ,2 ]
Zieg, Jakub [1 ,2 ]
机构
[1] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic
[2] Motol Univ Hosp, Prague, Czech Republic
[3] Hungarian Acad Sci, Dept Med 3, Budapest, Hungary
[4] Hungarian Acad Sci, MTA SE Res Grp Immunol & Haematol, Budapest, Hungary
[5] Inst Hematol & Blood Transfus, Prague, Czech Republic
[6] Charles Univ Prague, Fac Med 2, Dept Cardiovasc Surg, Prague, Czech Republic
关键词
Alternative complement pathway; Anti-complement factor H antibodies; Atypical haemolytic uraemic syndrome; Children; DGKE; Next-generation sequencing; FACTOR-H-AUTOANTIBODIES; COMPLEMENT MUTATIONS; ECULIZUMAB; IMPACT; GENE; CFHR1;
D O I
10.1007/s00431-020-03666-9
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Atypical haemolytic uraemic syndrome is an ultra-rare, life-threatening disease. Causative variants in genes that encode complement factors can be identified in 40-70% of cases. We performed genetic analysis of 21 Czech children with atypical haemolytic uraemic syndrome. Genetic or acquired predisposition to the disease was identified in the majority of our patients: CFHR1 and CFHR3 deletions in 14/21 (67%; 13 of them were positive for anti-complement factor H antibodies), variants in complement genes or DGKE in 13/21 (62%). Multiple genetic findings were identified in eight patients (38%). The incidence of atypical haemolytic uraemic syndrome in the Czech paediatric population was estimated to be 0.092 (CI 0.053-0.131) cases per million inhabitants and 0.92 (CI 0.53-1.32) cases per 100,000 births for the entire reporting period. Ten patients were initially treated with plasma exchange and eight with eculizumab or with a combination of eculizumab and plasma exchange. At the last follow-up, 20 patients were alive and one patient had end-stage renal disease. Conclusion: The incidence of atypical haemolytic uraemic syndrome in the Czech paediatric population corresponds to the reported incidence in Europe. We detected the unusually high rate of CFHR1/CFHR3 deletions associated with anti-complement factor H antibodies in Czech paediatric patients. Treatment by eculizumab led to superior outcomes and prevention of the disease relapses compared with plasma exchange therapy. Our results may help to understand the polygenic nature of atypical haemolytic uraemic syndrome as a disease that results from a combination of various risk factors.What is Known: center dot Atypical haemolytic uraemic syndrome (aHUS) is considered a polygenic and multifactorial disease. Genetic predisposition to aHUS is identified in 40-70% of children. center dot Anti-complement factor H antibodies are usually found in 6-25% of affected children.What is New: center dot Potentially causative genetic or acquired factors were confirmed in the majority of patients. The prevailing finding was the unusually high rate of CFHR1/CFHR3 deletions associated with anti-complement factor H antibodies (62% of patients). center dot The incidence of aHUS in Czech children is 0.092 (CI 0.053-0.131) cases per million inhabitants and 0.92 (CI 0.53-1.32) cases per 100,000 births for the entire reporting period.
引用
收藏
页码:1739 / 1750
页数:12
相关论文
共 50 条
  • [31] An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document
    Campistol, Josep M.
    Arias, Manuel
    Ariceta, Gema
    Blasco, Miguel
    Espinosa, Mario
    Grinyo, Josep M.
    Praga, Manuel
    Torra, Roser
    Vilalta, Ramon
    Rodriguez de Cordoba, Santiago
    NEFROLOGIA, 2013, 33 (01): : 27 - 45
  • [32] How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome
    Scully, Marie
    Goodship, Tim
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (06) : 759 - 766
  • [33] Eculizumab: A guide to its use in atypical haemolytic uraemic syndrome
    Keating G.M.
    Drugs & Therapy Perspectives, 2014, 30 (5) : 166 - 172
  • [34] Atypical haemolytic uraemic syndrome: a case report of a rare cause of reversible cardiomyopathy
    Campbell, Courtney M.
    Cassol, Clarissa
    Cataland, Spero R.
    Kahwash, Rami
    EUROPEAN HEART JOURNAL-CASE REPORTS, 2020, 4 (02)
  • [35] Kidney transplantation in atypical haemolytic uraemic syndrome (aHUS): a cheap way out?
    Bemelman, F. J.
    ten Berge, I. J. M.
    NETHERLANDS JOURNAL OF MEDICINE, 2013, 71 (07) : 339 - 341
  • [36] Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions
    Bekassy, Zivile D.
    Kristoffersson, Ann-Charlotte
    Cronqvist, Mats
    Roumenina, Lubka T.
    Rybkine, Tania
    Vergoz, Laura
    Hue, Christophe
    Fremeaux-Bacchi, Veronique
    Karpman, Diana
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 (11) : 2899 - 2907
  • [37] Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis
    Socie, Gerard
    Caby-Tosi, Marie-Pierre
    Marantz, Jing L.
    Cole, Alexander
    Bedrosian, Camille L.
    Gasteyger, Christoph
    Mujeebuddin, Arshad
    Hillmen, Peter
    Vande Walle, Johan
    Haller, Hermann
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (02) : 297 - 310
  • [38] Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab
    Gately, Ryan
    San, Aye
    Kurtkoti, Jagadeesh
    Parnham, Alan
    NEPHROLOGY, 2017, 22 : 32 - 35
  • [39] Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis
    Legendre, Christophe M.
    Campistol, Josep M.
    Feldkamp, Thorsten
    Remuzzi, Giuseppe
    Kincaid, John F.
    Lommele, Asa
    Wang, Jimmy
    Weekers, Laurent E.
    Sheerin, Neil S.
    TRANSPLANT INTERNATIONAL, 2017, 30 (12) : 1275 - 1283
  • [40] Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature
    Manenti, Lucio
    Gnappi, Elisa
    Vaglio, Augusto
    Allegri, Landino
    Noris, Marina
    Bresin, Elena
    Pilato, Francesco Paolo
    Valoti, Elisabetta
    Pasquali, Sonia
    Buzio, Carlo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 (09) : 2246 - 2259